Tags : Multiple Chronic Inflammatory Diseases

Biosimilars

Celltrion Receives EC’s Approval for Yuflyma (biosimilar, adalimumab) for the

Shots: The EC approval follows CHMP’s positive recommendation for Yuflyma (high concentration formulation) granted in Dec’2020. The approval covers all 13 intended indications to treat multiple chronic inflammatory diseases The approval is based on analytical, pre/ clinical studies, demonstrating that Yuflyma is comparable to the reference product, in terms of safety, efficacy, PK/PD, and immunogenicity […]Read More